Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Advertisement
Novel Inflammasome inhibitor, which uniquely targets ASC, represents a differentiated approach to block abnormal immune responses driving the onset of inflammatory diseases